Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vumerity in Peripheral Artery Disease
NCT06319339Phase 1Recruiting
- Sponsor
- University of Nebraska
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of diroximel fumarate in peripheral artery disease (PAD) (4 arms), sponsored by University of Nebraska. Primary endpoints: Macrovascular Endothelial Function at Day 7, Oxygen Transfer and Utilization at Day 7 and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
diroximel fumarate
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT06319339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319339.